-
Disease Description
Glaucoma is a disease in which the optic nerve is damaged, leading to progressive, irreversible loss of vision. It is often, but not always, associated with increased pressure of the fluid in the eye.
The nerve damage involves loss of retinal ganglion cells in a characteristic pattern. There are many different sub-types of glaucoma but they can all be considered as a type of optic neuropathy. Raised intraocular pressure is a significant risk factor for developing glaucoma (above 22 mmHg or 2.9 kPa). One person may develop nerve damage at a relatively low pressure, while another person may have high eye pressure for years and yet never develop damage. Untreated glaucoma leads to permanent damage of the optic nerve and resultant visual field loss, which can progress to blindness.
Glaucoma can be divided roughly into two main categories, "open angle" and "closed angle" glaucoma. Closed angle glaucoma can appear suddenly and is often painful; visual loss can progress quickly but the discomfort often leads patients to seek medical attention before permanent damage occurs. Open angle, chronic glaucoma tends to progress more slowly and the patient may not notice that they have lost vision until the disease has progressed significantly.
Glaucoma has been nicknamed the "sneak thief of sight" because the loss of vision normally occurs gradually over a long period of time and is often only recognized when the disease is quite advanced. Once lost, this damaged visual field can never be recovered.
Prevalence
Worldwide, it is the second leading cause of blindness. It is also the first leading cause of blindness among African Americans. Glaucoma affects 1 in 200 people aged fifty and younger, and 1 in 10 over the age of eighty. If the condition is detected early enough it is possible to arrest the development or slow the progression with medical and surgical means.
Current Treatments
Glaucoma treatment may include prescription eye drops, laser surgery, or microsurgery.
Evidence for and Proposed Mechanism for Cannabinoid Therapeutics
The retinal system could benefit from use of cannabinoids, according to the study Endocannabinoids in the Retina: From Marijuana to Neuroprotection” from the Department of Neurobiology and Behavior at Stony Brook University in New York: “The purpose of this review is to introduce the "cannabinergic" field to the retinal community. All of the fundamental works on cannabinoids have been performed in non-retinal preparations, necessitating extensive dependence on this literature for background. Happily, the retinal cannabinoid system has much in common with other regions of the central nervous system. For example, there is general agreement that cannabinoids suppress dopamine release and presynaptically reduce transmitter release from cones and bipolar cells. How these effects relate to light and dark adaptations, receptive field formation, temporal properties of ganglion cells or visual perception are unknown. The presence of multiple endocannabinoids, degradative enzymes with their bioactive metabolites, and receptors provides a broad spectrum of opportunities for basic research and to identify targets for therapeutic application to retinal diseases.”
Another study at the University of Aberdeen in the United Kingdom also points out the positive impact cannabinoids could have on glaucoma: “Glaucoma is one of the leading causes of blindness in the world. In spite of the diverse therapeutic possibilities, new and better treatments for glaucoma are highly desirable.
Cannabinoids effectively lower the intraocular pressure (IOP) and have neuroprotective actions. Thus, they could potentially be useful in the treatment of glaucoma. The purpose of this article is to provide the reader with an overview of the latest achievements in research into the potential use of cannabinoids for glaucoma.”
-
Category
Critical Ailments -
Created
Thursday, 16 March 2017 -
Group admin
CBIS
American States University
*** Warning this document contains graphic images.
Click the above Image to Review our Cancer Drug Comparables
Click the above Image to Review our 1-Million Strong FC, Media Kit
*** Warning this document contains exciting images.
Click the surrounding Images to become one of the First 1-Million Strong Killing Cancers, Fight Club Members to help 'Make that Change' Join in Now! *** Warning this Membership contains Exciting Results.
PS ... ALL of our CSi-VIP's, CSi-GIFT Share Recipients (Paid Processing Fees), CSi-Award Recipients, and those who Donated through the GO-Fund-Me Promotion are ALL Automatically included as "1-Million Strong Killing Cancers, Fight Club Members!"
You do not need to purchase anything, you are ALREADY included in the "First" 1-Million Membership Club, CONGRATULATIONS !!!
Please Click the Calendar image below to book your time to speak with Mr. Dabney about "Your Final CSi-VIP Shareholder Legacy".
ALL of your PREVIOUS Cannabis Science (CBIS) Shares are on Record with the Company and with the Transfer Agent (As Confirmed by the SEC).
The Company does NOT have your Original trading CBIS Shares, either you have them, or your Brokerage Firm has them (with new identifier codes) or the Transfer Agent has them.
You can confirm with your Broker (Please obtain an Official Brokerage Firm Letter Representing where your CBIS shares are).
Your CBIS GIFT Shares are on Record Books with the Company and/or in your possesion for Regulatory submissions, Registered Legal Opinion Letters, and awaiting Final Audit for Final Trading approvals.
Your CBIS Shares are legal tender and we are ALL waiting for the FINAL Confirmations for trading once the Audits and Legal Filings are completed.
*** We will announce the FINAL CBIS acquisition changes and Corporate Mergers once the filings are completed, so as long as you know where your CBIS Shares are, you are GOOD.
As clearly stated by Mr. Dabney "Our History is Building up into our Inaugural Event of our Lifetime, the Inaugural 1-Million Strong Killing Cancers, Fight Club, VIP Fundraiser Event, dubbed, 'Celebrities Raising $20 Million to Keep Killing Cancers' the Initiative is fueled further with the '1- Million Strong Killing Cancers, Variety Television Show' through the ASU 'Make that Change Campaign'. Hence the accumulation of 1-Million people donating $20 each, because we are ALL Celebrities in our own Rights.
This is More than enough Funding to begin our FDA Clinical Trials for our 'Low-Cost Cancer Drugs' to treat millions Worldwide that already has proven HARVARD Award Winning Cancer Killing Success!
AND
This is also PLENTY of Funding to bring ALL our CBIS Shares back trading again and follow through with our Original Complete Cannabis Science Share trading Game Plan, and We Win, once again. Hopefully we'll see you at the Event to help 'Make that Change'!"
Should you have any further questions regarding your CBIS Shares or additional Share Ownership, Please Click the above Calendar Link to book your time to speak with Mr. Dabney about "Your Final CSi-VIP Shareholder Legacy".
The ASU Digital Business HUB will be used as the main business student learning center. GBXI will be the main pivot point to spin out trading shares of all our Partner Public and Private Companies such as Cannabis Science, iCannabinoid, Thermic Science, LNC, LMG, and a few more old and new school surprises for our loyal shareholders. No one will be missed! A true Digital Business HUB for students, just as planned all along.
Each spinout company will give our GBXI registered shareholders additional pro-rata shares in each spinout company over and above their original shares in each entity. This provides the required shareholder base for each company required to trade and gives additional shares to all our loyal GBXI shareholders.
We call this “Compounding our Wealth” through extra spinout share participation for all our loyal GBXI shareholders. Each registered GBXI shareholder will receive additional shares of each spinout Company over and above their original shares to enjoy additional liquidity as each company begins to trade through the GBXI Digital Business HUB spinout process.
Click here to review the Report:
Case No. 2:17-CV-02271-KJM-JDP
Inspire, Dream, Change
YOUR DIGITAL ERA Personal & Business Access Learning HUB
Observational Studies
Photos
Activity Stream
Still sitting on CBIS shares... what gives?
I periodically check in on this site, but it's so poorly organized that it's impossible to find anything other than Mr. Dabney's cheerleading posts....
Investor Relations
Investor Relations
Adding investor value is of paramount importance to Cannabis Science. One way we do this is to service potential and existing shareholders. We are...
Cannabis Science Inc. "Shareholder Loyalty Gift Center of Excellence"
HARVARD Award Winning
CANCER Killing Success
1st HARVARD Award Winning
Stage 4 Lung Cancer Killing Article:
*** Please click image below.
2nd HARVARD Award Winning
Stage 4 Lung Cancer Killing Article:
*** Please click image below.
*** PLUS
(3) other Cannabis Science
REAL WORLD Successes:
Stage 4 Breast Cancer
Skin Cancer
Karposis Sarcoma
Cannabis Science CEO, Presents …
The FINAL “CBIS GIFT Shares” Issuances!
DECEMBER 1, 2022, Cheers! & HAPPY HOLIDAYS !!!
ALL GIFT Shares 1, 2, & 3 being ISSUED !!!
LAST Steps:
Please confirm Yours NOW !!!
1. CONFIRM Correct Total Share Amount(s)
2. CONFIRM Correct Name(s) on CERTIFICATE
3. CONFIRM Correct Mailing Address
ASU/CSi-EDP-ECO-System
At it's FINEST !!!
WHICH ONE ARE YOU ??
Those who, MAKE things happen.
Those who WATCH things happen.
Those who WONDER what the ... HAPPENED ???
We can make this HAPPEN way FASTER Working as a TEAM !!!
WHAT Matters is how much you CARE about KILLING CANCERS ...
This is it ... We are ALL Here ... Now ... with a Bunch of Celebrities going on TV Worldwide to Start raising $20 Million to Keep Killing Cancers.
2023 Audit considerations NASDAQ.
Cannabis Science Inc.
Share Structure 2023
Par Value: $0.001 USD
Last Price: $0.00647 USD
OTC Markets.
Common Stock:
Authorized:
5,000,000,000
Issued:
2,521,095,296
Class A Common Stock
Authorized:
100,000,000
Issued:
0
Class B Common Stock
Authorized:
1,500,000,000
Issued:
0
Preferred Stock
Authorized:
1,000,000
Issued:
1,000,000
Sign up for a FREE Assessment to JOIN the UNIVERSITY Team or any ASU/CSi-EDP Team for whatever your AREA of Expertise is … then say no more… you already know.
You already know our Extensive LIST of GROUNDBREAKING Products.
1-Million STRONG TV Coverage, HARVARD Award Success.
TAKE YOUR PICK AND BECOME A PART OF HISTORICAL CHANGE
*** APPLY for FREE in CONFIDENCE and Success.
Each Product launch WE RELEASE will include Equity Participation according to standard salaries and share bonus structures.
EVERYONE sign up to add your STRENGTHS to OUR COMBINED SUCCESS and lets MAKE THIS HAPPEN NOW !!!
